BRPI0606619A2 - método de análise de oligossacarìdeos, a partir do plasma sangüìneo - Google Patents

método de análise de oligossacarìdeos, a partir do plasma sangüìneo

Info

Publication number
BRPI0606619A2
BRPI0606619A2 BRPI0606619-4A BRPI0606619A BRPI0606619A2 BR PI0606619 A2 BRPI0606619 A2 BR PI0606619A2 BR PI0606619 A BRPI0606619 A BR PI0606619A BR PI0606619 A2 BRPI0606619 A2 BR PI0606619A2
Authority
BR
Brazil
Prior art keywords
analysis
blood plasma
oligosaccharides
molecular weight
low molecular
Prior art date
Application number
BRPI0606619-4A
Other languages
English (en)
Inventor
Pierre Mourier
Christian Viskov
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0606619A2 publication Critical patent/BRPI0606619A2/pt
Publication of BRPI0606619B1 publication Critical patent/BRPI0606619B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8836—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving saccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODO DE ANáLISE DE OLIGOSSACARìDEOS, A PARTIR DO PLASMA SANGüìNEO. A presente invenção refere-se a um método de análise dos oligossacarídeos, que constituem as heparinas de baixo peso molecular e as heparinas de peso molecular muito baixo, a partir do plasma sanguíneo.
BRPI0606619A 2005-01-19 2006-01-18 método de análise de oligossacarídeos, a partir do plasma sangüíneo BRPI0606619B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500554A FR2880951B1 (fr) 2005-01-19 2005-01-19 Methode d'analyse d'oligosaccharides a partir de plasma sanguin
PCT/FR2006/000112 WO2006077317A1 (fr) 2005-01-19 2006-01-18 Methode d'analyse d'oligosaccharides a partir de plasma sanguin

Publications (2)

Publication Number Publication Date
BRPI0606619A2 true BRPI0606619A2 (pt) 2009-07-07
BRPI0606619B1 BRPI0606619B1 (pt) 2016-12-13

Family

ID=35385848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606619A BRPI0606619B1 (pt) 2005-01-19 2006-01-18 método de análise de oligossacarídeos, a partir do plasma sangüíneo

Country Status (14)

Country Link
US (1) US7575930B2 (pt)
EP (1) EP1842070B1 (pt)
JP (1) JP5203714B2 (pt)
KR (1) KR20070103387A (pt)
CN (1) CN101107526B (pt)
AR (1) AR051905A1 (pt)
AU (1) AU2006207440B2 (pt)
BR (1) BRPI0606619B1 (pt)
CA (1) CA2591631A1 (pt)
FR (1) FR2880951B1 (pt)
IL (1) IL184417A (pt)
MX (1) MX2007008791A (pt)
RU (1) RU2415436C2 (pt)
WO (1) WO2006077317A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2020252677A1 (zh) * 2019-06-19 2020-12-24 北京三元食品股份有限公司 乳中游离低聚糖的高通量定量测定方法
CN115112799B (zh) * 2022-06-30 2023-02-28 北京三元食品股份有限公司 一种定性检测母乳中酸性低聚糖的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
JPH02227144A (ja) * 1989-02-28 1990-09-10 Asahi Chem Ind Co Ltd 陰イオン交換体及びそれを充填した糖類分離用液体クロマトグラフィー用カラム
US5843786A (en) * 1995-11-28 1998-12-01 Neose Technologies, Inc. Analysis of carbohydrates in biological fluids by high performance liquid chromatography
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6617316B1 (en) * 1999-10-22 2003-09-09 Aventis Pharma Oligosaccharides, their preparation and pharmaceutical compositions containing them
CA2478700C (en) * 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
AU2003279430B2 (en) * 2002-09-23 2008-09-11 Aventis Pharma S.A. Method of determining specific groups forming heparins
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
FR2844808B1 (fr) 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire

Also Published As

Publication number Publication date
EP1842070A1 (fr) 2007-10-10
RU2007131442A (ru) 2009-02-27
US20080009069A1 (en) 2008-01-10
AU2006207440B2 (en) 2011-04-21
FR2880951B1 (fr) 2015-09-18
CN101107526B (zh) 2013-08-14
IL184417A0 (en) 2007-10-31
RU2415436C2 (ru) 2011-03-27
US7575930B2 (en) 2009-08-18
WO2006077317A1 (fr) 2006-07-27
AR051905A1 (es) 2007-02-14
KR20070103387A (ko) 2007-10-23
BRPI0606619B1 (pt) 2016-12-13
EP1842070B1 (fr) 2016-04-13
IL184417A (en) 2011-10-31
AU2006207440A1 (en) 2006-07-27
JP2008527390A (ja) 2008-07-24
CN101107526A (zh) 2008-01-16
MX2007008791A (es) 2007-09-11
CA2591631A1 (fr) 2006-07-27
JP5203714B2 (ja) 2013-06-05
FR2880951A1 (fr) 2006-07-21

Similar Documents

Publication Publication Date Title
BRPI0606619A2 (pt) método de análise de oligossacarìdeos, a partir do plasma sangüìneo
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BRPI0717822A2 (pt) Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
MA32934B1 (fr) Combinaisons inhibitrices hsp90
BRPI0818374A8 (pt) Substratos porosos hidrofílicos
WO2007098184A3 (en) Methods and compositions for analyte detection
BRPI0919281A2 (pt) processo e sistema de lubrificacao de uma turbomáquina, e, turbomáquina
BRPI0720153A8 (pt) Composições e artigos que contêm uma matriz de polímero reticulada e um líquido ativo imobilizado assim como processos de utilização dos mesmos
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
ECSP109968A (es) Depsipéptidos cíclicos
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
ATE524076T1 (de) Niedrig-glykämische mischungen
BR112012014060A2 (pt) métodos e reagentes para detecção aprimorada de peptídeos beta-amiloides
WO2007035872A3 (en) Tdf-related compounds and analogs thereof
FR2897063B1 (fr) Polypeptides reconnus par des anticorps anti-trichinella, et leurs applications.
EA200900261A1 (ru) Применение эсцина
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
BR112012021944A2 (pt) novos agentes de cura
BRPI0818409B8 (pt) Método de identificação de uma planta de milho ou germoplasma que apresenta resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivirus, ou suscetibilidade a um membro do sorogrupo 2 de fijivírus, método de produção de uma planta de milho apresentando resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivírus e método de seleção de pelo menos uma planta de milho através de seleção assistida por marcador de um lócus de traço quantitativo associado com a resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivírus
NO20091386L (no) Fenyloksyanilinderivater
EA200970074A1 (ru) Химический способ создания давления

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2614 DE 09-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.